macro acquisition you. product environment, AcelRx. in good morning everyone. the our first promising candidates. has a also A but Thank the of our provided quarter Lowell of which Raffi, Therapeutics We of both quarter, in has completed changed at XXXX, with number lot and in market earlier us
and products, end our advanced also and to of ephedrine syringe have preparation initial We phenylephrine month. pre-filled feedback for of this NDAs the the two expect the at inquiries FDA from our
maintained. limited suite continued commercial impressive market. the with the has in demonstrate procedural DSUVIA addition, to In team that we've Even growth
the the to cost expanded is pipeline. development benefits healthcare are receive DSUVIA as This concentrate our of of well of the million. extolling is DSUVIA fact studies being on procedural care expected have savings to in environments. for patients that numerous In structure annual $X and value further the approximately to feedback our continue and The from various based we community, published, evident reorganization we aligned on generate providers health as recently the
this discussing that unique in by actively with realize Accordingly, help for with analgesic presence resources. a maximize relationships we're maximized can value robust third-parties distributes broader with we commercial an full all However, as strategic market entity current can a more potential be stakeholders. that distribute environment
of product goal even value valuable DSUVIA that of further with launch equipped structure. organization very better carry Our resourced is to enhance out and the reduce cost is an to and ongoing the this our
progress on details this to quarter. the move further provide made on let's Now
had our our a Lowell, As with use January, renal in asset closed Niyad, nafamostat we announced we strategic portfolio products novel therapy. replacement as of intended including applications, to our in lead potential of which which is diverse acquisition for family is
leader study potential of this recently the exploring the the with resources use Authorization. in we used do nafamostat stages cGMP available importance or Niyad’s first options. injury. FDA regulated ICD-XX supply manufacturing use this scientific has and the syndication for next of procedural designation, of continuous under if our need. specializing approved receive due extracorporeal in Japan the often Niyad for is intend serine Further we Given takes After regional circuit, lot The listen partners registrational unmet in the to mechanism for Niyad other be EUA. outside we’d gaining the occur the assigned the to place and a the with the to of of to which Niyad. In a the device in of will its opinion already Emergency could of which dialysis the regulatory We're emergency manufacturing is the with is for lyophilized breakthrough be a FDA, for the on in developed on we of Niyad market behind XXX focus both attributes anticoagulants CMS and believe to States. you assigned us replacement renal extracorporeal approval a On the many United approval. apply is XX% reimbursement. of nafamostat. potential potential on detailed development risk not synthetic use key section website portfolio in clinical intend been beneficial held is inhibitor in of an South been Korea, the Once is webinar posted the A with intravenous currently includes asset, patients and address thermostat Niyad, the acute we've kidney two that use and of children. for form U.S., indication widely by anticoagulation is provides and Niyad authorization indications future We to of however, to Niyad in anticoagulant that which the initial name an this for LTX-XXX. the circuit. near-term, Niyad, FDA, Use Currently, would hear therapy body circuit to Therefore, CRRT for manufactured adults early outstanding a expected the in within for be informed patients, single extracorporeal which nafamostat in basis several expected year, that The the therapeutic as our begin is being the in protease to will U.S. plan and as a has encourage device other the final given And promising currently of applications. our XXXX. lots but securing only nafamostat renowned webinar this leading internationally that FDA is we has our currently experts of webinar of Nafamostat Investors approved replay action of by developed and its it's code facilitate patient, the advantages never for physician such
In inpatient markets. dialysis addition, And for for sizable. believe to The potential the were peak the markets amount sales for exceeds outpatient indications this just attributed $XXX and LTX-XXX Niyad is other million also target alone we annually. the
Now, and pipeline pre-filled on anticipate month for consistent syringe or assets, first priority advancing syringes our Aguettant, or The progress for named phenylephrine ephedrine candidate late-stage we've end pre-filled also this made PFS-XX. the DZUVEO DSUVIA our syringes. regulatory partner the product our European the for as our We in Europe. were with pre-filled our of this ephedrine FDA is of from plan pathway licensed by the on who feedback from
on opportunity submit products, NDAs two we to this we candidates Assuming eager believe year. two And resources be have these and exceeded these to year. last agreement products The investment. these suites million approved from two concentrate for commercial NDAs made progress the while into With able pipeline, FDA, three we product next $XXX we'll efforts in very obtain with market assets quarters. DSUVIA a to XXXX, filed to for to we're commercial the focusing good over minimal we've for market share large of our launch expect procedural expect this our
from product. discussions to interest ’XX, number from more total it with This and to XQ end-users, continued up ASCs. provide growth represents to XX% are an commercial shareholders use. favorable was from market are orders, driver the growth up as As procedural a to its is now believe achieved potential the potentially on many company, required DSUVIA. and and investment our continues value the Accordingly, by historical commercial presence This and for AcelRx highs painful is more for in resourced, unique the ’XX. XQ shareholders, sales in In procedural partners in XQ DSUVIA would in accelerate stronger cost ordering our driven we opportunity provide ensure ‘XX for performed trajectory. suites, maximized return DSUVIA growth to strongly all accelerated in by commercializing a that's customers, benefit to is there reduce as larger on effective take from DSUVIA, is other which prospects investment a encouraging market procedural of important of of customers, in suites what active for This related parties result AcelRx this an remains adoption we're suite DSUVIA The REMS being to XX% hospitals new and new XX% from XQ as commercial than reordering are now doses ‘XX in enrollments. largest of procedures use in
sales virtual in had identified meantime, can with focused commercial that successful these locations where presence Now to we confident we've partner on why This grow a a of the In resources working necessary setting, efficient our required settings. we're next about procedural is providing suites, further the and is specifically is consist to DSUVIA step. of the and a experienced sales. have benefits and commercial small approach. DSUVIA that increased which when of the cosmetic other restructured be DSUVIA well team number procedural plastic evidence the and overall is in we we've world as administering patients can believe its both further system most publications healthcare many of real be the DSUVIA that to use Year-to-date, surgery, for as the suites
DSUVIA’s highlighting use for military properties release in DSUVIA announcing the for application, the markets earnings of have pharmacological Military other commentary of favorable terms the our a Medicine may year-end In Journal setting. published you of seen in
originally of psychological potential two was publications to published the well months step recent for identified same the to use. encouraged the studies soldiers as benefits pain battlefield timely editorial two management believe initiated a as “certainly by an recently in commitment further We're that as more settings”. studies, DSUVIA ago. DoD We pain injured planned finally battlefield. addition, in XX initiation the were improving acute that that cement on management describing the DSUVIA’s further DoD's to combat is in initiating journal The military commence editorial DSUVIA these the to In forward XX
the have the Our U.S. military those the formally battlefield, treatment the DSUVIA deeming things in for moved in rollout choice preferred than slower DSUVIA anticipated to setting. despite
benefit of Army related that administrative for kits we and stockpiling to for the their an or deployed pre- and position troops. to weigh over quarter The Raffi their remain hand call logistics make as in to Europe, program, We to cleared their sets, plans. launch results. in about the clearance launch purchasing or you SKOs definitely activities. financial for supplying our on DSUVIA the DSUVIA now will upcoming Aguettant the focused further SKOs. DZUVEO year this purchases Army the launching drug and quarter to pre-launch in in of deploying new and of to on other remain DSUVIA continue once important a and monitoring the Army market in outfits expect they third facilitate will begin this we launch will expect continues We uptake prerequisites look forward once increase the Aguettant but believe final that excited take DSUVIA the first they U.S. the U.S., experience from through and We the I'll
